Updated:
Dubai hospital buying AI? What the vendor must disclose and who validates it
A Dubai Health Authority policy lists what an AI vendor must tell you and asks for independent validation. Here is the list, so you can put it in your next proposal review.
When a vendor presents an AI product to a Dubai hospital, the questions that matter are rarely on the slides. The Dubai Health Authority (DHA) policy “Artificial Intelligence in the Healthcare” (reference DHA/HISHD/PP-09) turns many of them into a list. Its control table gives an issue date of 1 July 2021, an effective date of 1 October 2021 and a revision date of 1 July 2026, so check DHA for a newer version before you rely on this summary.
Who it covers
The policy applies to DHA-licensed facilities and professionals that use AI, to national and locally based international AI developers that use Dubai data, and to UAE-based pharmaceutical manufacturers, health insurers, public health entities and researchers using AI in Dubai.
What a vendor must disclose
The policy says the disclosure about an AI solution must cover:
- which functions are AI-enabled;
- how the solution was validated;
- which data sets were or must be used;
- the expected outcomes;
- the healthcare professional’s role in the final decision;
- the type of algorithm;
- the ethical examination of how data is used;
- how performance must be validated;
- how the solution is integrated into care; and
- the limits of the data and algorithms.
You can turn that list straight into a vendor questionnaire. A vendor who cannot answer “what are the limits of your data?” in writing has told you something useful.
Independent validation
All AI solutions for healthcare must also go through independent validation by a competent third party. A vendor’s own validation study is the start of the conversation, not the end of it.
Oversight after go-live
AI solutions with a significant effect on people’s lives must be designed so that designated end users can override them or reverse their decisions, and they must have built-in appeals procedures. Performance must be monitored in clinical practice and actual outcomes compared with those from training and validation; significant gaps lead to further inspection. End users must report incidents and patient-safety issues to DHA’s Health Regulation Sector and have AI functionality audited regularly by an independent third party.
What a nurse leader can ask
- Who can override this tool on the ward, and how?
- What will we compare real results against?
- Who do staff tell when something looks wrong?
Key takeaways
- Dubai’s policy gives you a disclosure list to hold vendors to, plus independent third-party validation.
- Overrides, appeals, monitoring against validation results and incident reporting are part of the expected set-up.
- Check DHA for a version newer than the one dated 2021, and ask your compliance team how it fits with other Dubai rules.
- This is general information, not legal advice.
Sources: Dubai Health Authority, Artificial Intelligence in the Healthcare, DHA/HISHD/PP-09 (cover page and sections 1, 2, 4.2.3, 4.3.2, 4.3.3, 4.4.2, 4.6.11, 4.8.1, 4.8.2, 4.8.5). Read on 15 November 2026.